Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali
NCT00863408 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2017-07-02
Summary
Background:
* P. falciparum, one of the most virulent forms of malaria, causes more than 300 million episodes of malaria and 1 million deaths each year. The spread of drug-resistant parasites, insecticide-resistant mosquitoes, and persistent socioeconomic conditions of poverty compound the difficulties of malaria as a major global health problem. New means of disease and vector control are vitally needed.
* Several promising strategies rely on targeting mosquito populations when they are most vulnerable, such as during the dry season when mosquitoes find it difficult to reproduce. Large regions of the West African country of Mali have prolonged dry seasons (up to 8 months), during which mosquito populations dramatically decline within a month after the rainfall ceases. Clearly, mosquitoes can survive the dry season (as evident from their robust numbers during the wet season) but the process that enables them to do so remains unknown. Targeting the small and fragile mosquito population at the end of the dry season could reduce or eliminate the numbers of mosquitoes in certain regions, providing great benefits for communities in dry regions.
Objectives:
* To determine if common malaria-carrying mosquitoes survive the dry season in the Mali village of Thierola by estivation (going dormant, or hibernating, during dry periods).
* To identify and examine mosquitoes that were marked with special paint during a previous protocol, if these marked mosquitoes are captured during the investigation.
Eligibility:
* All activities in this protocol will take place in Thierola village, Banamba district, Koulikoro region, Mall, West Africa. The village was chosen because it is isolated from other communities by at least 6 km and is a small community of less than 300 inhabitants living in 90 houses.
* Participants will be healthy adult men between 18 and 65 years of age.
Design:
* Thirty adult men who live in Thierola will be recruited to participate as mosquito collectors for the human-baited trapping method and will work in teams of two.
* The first collector will expose his lower legs to attract human-seeking mosquitoes. Using a mouth aspirator, the second collector will collect the mosquitoes as they land on the first collector's legs.
* The collections will be conducted both indoors and outdoors from 6 p.m. to 6 a.m. the following morning for 14 consecutive days.
* All study volunteers will be trained in proper collection technique and supervised throughout the study by a mobile team led by the study investigators. Volunteers will be monitored for signs of malaria and treated accordingly if they develop symptoms of the disease.
* Researchers will collect mosquito samples at the end of the dry season (April-May) and at the start of the rainy season (May-June).
* Mosquitoes collected in the study will be analyzed by NIH researchers to learn more about how they survive during the dry season.
Conditions
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-03-03
- Completion
- 2010-03-10
Countries
- United States
Study Locations
More Related Trials
-
Spatial Repellents for Vector Control
NCT04795648 ·Status: COMPLETED ·Phase: NA
-
Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
NCT01160562 ·Status: COMPLETED
-
A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya
NCT00666380 ·Status: COMPLETED ·Phase: PHASE1
-
Experimental Vaccine for Plasmodium Falciparum Malaria
NCT00340431 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum
NCT00487916 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali
NCT02334462 ·Status: COMPLETED ·Phase: PHASE1
-
Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
NCT03917654 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
NCT00460525 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults
NCT01988636 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria
NCT00414336 ·Status: COMPLETED ·Phase: PHASE1
-
Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing
NCT04034264 ·Status: RECRUITING
-
Experimental PfSPZ Vaccine in Adults Without Malaria
NCT01441167 ·Status: COMPLETED ·Phase: PHASE1
-
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
NCT06607003 ·Status: RECRUITING ·Phase: PHASE1
-
A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali
NCT01322581 ·Status: COMPLETED
-
Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)
NCT05652504 ·Status: SUSPENDED ·Phase: PHASE1
-
Study of Factors Involved in Resistance to Severe Malaria
NCT00368810 ·Status: COMPLETED
-
Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali
NCT00889616 ·Status: COMPLETED ·Phase: PHASE1
-
Malaria Vaccine Pilot Evaluation
NCT03806465 ·Status: COMPLETED
-
Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults
NCT01540903 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
NCT01540474 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
NCT02014727 ·Status: COMPLETED ·Phase: PHASE1
-
Experimental Vaccine for Malaria
NCT00114010 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Pediatric FMP2.1/AS02A Trial in Mali
NCT00358332 ·Status: COMPLETED ·Phase: PHASE1
-
Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)
NCT01434381 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali
NCT02627456 ·Status: COMPLETED ·Phase: PHASE1